Coeptis Therapeutics Holdings Inc

For the period ended Dec 31, 2023. Filed Mar 26, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 26, 2024

ZSQR$2.79-17.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COEPTIS THERAPEUTICS HOLDINGS, INC.
Date: March 25, 2024	By:	/s/ David Mehalick
		David Mehalick
		Chief Executive Officer (Principal Executive Officer)
Date: March 25, 2024	By:	/s/ Brian Cogley
		Brian Cogley
		Chief Financial Officer (Principal Financial and Accounting Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

Daniel Yerace
Signature	Title	Date
/s/ David Mehalick	Chief Executive Officer	March 25, 2024
David Mehalick	(Principal Executive Officer) and Director
/s/ Brian Cogley	Chief Financial Officer (Principal Financial and	March 25, 2024
Brian Cogley	Accounting Officer) and Director
/s/ Daniel Yerace	Director	March 25, 2024
/s/ Christopher Calise	Director	March 25, 2024
Christopher Calise
/s/ Christopher Cochran	Director	March 25, 2024
Christopher Cochran
/s/ Philippe Deschamps	Director	March 25, 2024
Philippe Deschamps
/s/ Tara DeSilva	Director	March 25, 2024
Tara DeSilva
/s/ Gene Salkind	Director	March 25, 2024
Gene Salkind

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.